普拉曲沙单药治疗复发/难治性外周T细胞淋巴瘤研究的汇总分析
该汇总分析纳入4项设计相似、监管要求的前瞻性临床试验共221例复发/难治性外周T细胞淋巴瘤患者,评估普拉曲沙的疗效与安全性及影响因素。客观缓解率40.7%,中位缓解持续时间9.1个月,无进展生存4.6个月,总生存16.3个月;结论进一步支持普拉曲沙用于复发/难治性外周T细胞淋巴瘤,亚组分析结果需前瞻性研究确认。
要点
- 221例复发/难治性外周T细胞淋巴瘤患者接受普拉曲沙,客观缓解率40.7%
- 中位缓解持续时间9.1个月,无进展生存4.6个月,总生存16.3个月
- 亚组探索性分析提示既往1线化疗较2线或≥4线疗效更优,需前瞻性研究确认
核心结论
- 汇总分析结果进一步支持普拉曲沙用于复发/难治性外周T细胞淋巴瘤患者。
- 亚组分析结果需前瞻性研究确认。
研究设计与样本
- 对4项设计相似、监管要求的前瞻性临床试验数据进行汇总分析。
- 研究人群221例,中位年龄59岁,男性占67.0%。
- 48.9%为外周T细胞淋巴瘤非特指型,21.3%为血管免疫母细胞性T细胞淋巴瘤,11.8%为间变性大细胞淋巴瘤ALK阴性。
主要发现
- 普拉曲沙中位治疗时间2.56个月(范围0.03-24.18)。
- 客观缓解率40.7%,中位缓解持续时间9.1个月,无进展生存4.6个月,总生存16.3个月。
- 最常见的治疗相关全级别不良事件为口腔炎、血小板减少、白细胞计数下降、发热和呕吐。
- 亚组探索性分析提示:既往1线化疗较2线或≥4线化疗疗效更优;外周T细胞淋巴瘤非特指型或间变性大细胞淋巴瘤较转化型蕈样肉芽肿疗效更优;普拉曲沙前接受化疗和移植较仅化疗或化疗联合其他非移植治疗疗效更优。
关键数值与推荐
- 客观缓解率40.7%,中位缓解持续时间9.1个月,无进展生存4.6个月,总生存16.3个月。
临床怎么用
- 原文结论为汇总分析结果进一步支持普拉曲沙用于复发/难治性外周T细胞淋巴瘤患者,并指出亚组分析结果需前瞻性研究确认。
局限性
- 亚组分析为探索性分析,原文指出需前瞻性研究确认其 findings。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed or refractory (R/R) mature natural killer cell and T-cell lymphoma have limited treatment options. To evaluate pralatrexate's performance and factors influencing its safety and efficacy in R/R peripheral T-cell lymphoma (PTCL), we performed a pooled analysis of data from 4 similarly designed, regulatory-mandated prospective clinical trials. Of 221 patients (median age, 59 years; 67.0% male) in the study population, 48.9% had PTCL not otherwise specified (PTCL-NOS), 21.3% angioimmunoblastic T-cell lymphoma, and 11.8% ALK-negative anaplastic large cell lymphoma (ALCL). Patients received pralatrexate for a median of 2.56 months (range, 0.03-24.18) and had a 40.7% objective response rate with a median duration of response of 9.1 months, progression-free survival 4.6 months, and overall survival 16.3 months. The most common treatment-related all-grade adverse events were stomatitis, thrombocytopenia, white blood cell count decrease, pyrexia, and vomiting. Subgroup exploratory analyses suggest improved efficacy with 1 prior line of chemotherapy vs 2 or ≥4 prior lines; PTCL-NOS or ALCL vs transformed mycosis fungoides; chemotherapy and transplant before pralatrexate vs chemotherapy alone or chemotherapy with other nontransplant treatments. In conclusion, these pooled analysis results further support using pralatrexate in patients with R/R PTCL. Prospective studies are needed to confirm the findings of subgroups analyses.
引用
- O'Connor OA, Ko BS, Wang MC, et al. Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma. Blood Adv. 2024. PMID: 38429077. doi:10.1182/bloodadvances.2023010441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。